期刊文献+

6B型肺炎球菌荚膜多糖-破伤风类毒素结合疫苗的制备及其免疫原性 被引量:4

Preparation and Immunogenicity of Pneomococcus Type 6B Capsular Po-lysaccharide - Tetanus Toxoid Conjugate Vaccine
下载PDF
导出
摘要 目的 制备6B型肺炎球菌荚膜多糖(6B-PNCPS)-破伤风类毒素蛋白(TT)结合疫苗,并研究其免疫原性。方法6B-PNCPS用溴化氰活化后与己二酰肼形成多糖-酰肼基衍生物,然后在蛋白活化剂碳二亚胺作用下将6B-PNCPS与TT进行共价结合。分别将其结合物及多糖免疫NIH小鼠,用ELISA检测小鼠血清中抗6B-PNCPS抗体。结果6B-PNCPS-TT结合物经凝胶色谱分析显示具有较6B-PNCPS更大的相对分子质量,多糖/蛋白比为1.42-1.66。结合物具有6B-PNCPS的血清学特异性,所诱生的抗6B-PNCPS特异性IgG抗体滴度与6B-PNCPS差异有显著意义。结论 用该法制备6B-PNCPS-TT结合疫苗,具有良好的免疫原性。 Objective To prepare and study the immunogenicity of pneomococcus type 6B capsular polysaccharide (6B - PNCPS) - tetanus toxoid (TT) conjugate vaccine. Methods 6B - PNCPS - IT was activated by Cyangen Bromide (CNBr) and reacted with adipic acid dihydrazide (ADH), then 6B - PNCPS - TT conjugate was prepared by carbodiimide - mediated coupling of 6B-PNCPS with tetanus toxoid (TT) . NIH mice were immunized with 6B - PNCPS - TT conjugate, using pure 6B - PNCPS as control, and the PNCPS antibody titers in the sera of them were detected by ELISA. Results Gel chromatography proved that, compared with that of 6B - PNCPS, the relative molecular weight of 6B - PNCPS - TT was large. The ratio of polysaccharide to protein was 1.42- 1.66. The conjugate vaccine showed the serological characteristic of 6B -PNCPS, and the liters of specific IgG induced by it was significantly higher than that induced by 6B - PNCPS. Conclusion The prepared 6B - PNCPS - TT conjugate vaccine showed good immunogenicity.
出处 《中国生物制品学杂志》 CAS CSCD 2002年第6期353-356,共4页 Chinese Journal of Biologicals
关键词 6B型肺炎球菌荚膜多糖 破伤风类毒素 疫苗 制备 免疫原性 共价结合菌苗 Pneumococcal capsular polysaccharide Tetanus toxoid Conjugate vaccine Immunogenicity
  • 相关文献

参考文献8

  • 1Koivula I,Sten M,Leinonen M,et al.Clinical efficacy of pneumococcal vaccine in the elderly:a randomized,single-blind population-based trial.Am J Med,1997,103(4):281-290.
  • 2Lee HJ,Kang JH,Henrichsen J,et al.Immunogenicity and safety of a 23-valent pneumococcal polysaccharide Vaccine in healthy children and in children at increased risk of pneumococcal infection.Vaccine,1995,13(16):1533-1538.
  • 3Bulter JC,Breiman RF,Lipman HB,et al.Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States,1978-1994:implications for development of a conjugate vaccine J Infect Dis,1995,171:885-889.
  • 4杨耀,栗克喜,宋绍忠,张云,江山,黄镇,谢全海,兰芳,黄健,毕俊红,邓雪莲,李凤祥,袁曾麟,郭淑英,石继春,何莉.23价肺炎链球菌荚膜多糖疫苗的研制[J].中国生物制品学杂志,2000,13(3):154-156. 被引量:15
  • 5Hausdorff WP,Bryant J,Paradiso PR,et al.The contribution of specific pneumococcal serogroups to different disease manifestations:Immplications for conjugate vaccine formulation and use.Part II.Clin Infect Dis,2000,30:122-140.
  • 6Vidarson G,Sigurdardottir ST,Gudnason T,et al.Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.Infect Immun,1998,66(6):2866-2870.
  • 7Rodriguez ME,Dobbelsteen GP,Oomen LA,et al.Imunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.Vaccine,1998,16(20):1941-1949.
  • 8Laferriere CA,Sood RK,Muys JM,et al.The synthesis of streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.Vaccine,1997,15(2):179-186.

二级参考文献5

  • 1[1]Recommendation of the public health service advisory committee on immunization practices pneumococcal polysaccharide vaccine. Morbidity and Mortality Weekly Report,1978,27(4):25.
  • 2[2]Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med,1964,60:759-776.
  • 3[3]Wenger J D, Hightower A W, Facklam R R, et al. Bacterial meningitis in the united states,1986:Report of a multistate surveillance study. J Infect Dis,1990,162:1316-1323.
  • 4[4]Fedson DS .Pneumococcal vaccine. In:Plotkin SA.Morhmer EA. Vaccines Philadelphia,Pa:WB Saunders Co,1988,271-299.
  • 5[5]Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation Pneumococcal capsular polysaccharide vaccine with emphasis oa the cross-reactive types withen groups. J Infect Dis,1983,148:1136-1159.

共引文献14

同被引文献71

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部